Browsing Tag
AstraZeneca
141 posts
Covid antibody candidate AZD7442 : AstraZeneca, US strike deal for additional doses
AstraZeneca has agreed to supply the US government with up to half a million additional doses of AZD7442,…
AstraZeneca’s Forxiga wins approval in China for heart failure treatment
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration…
India grants emergency approval to Covishield and Covaxin vaccines for Covid-19
In a significant development in the battle against Covid-19, the Drugs Controller General of India (DCGI) has granted…
India’s DCGI grants emergency approval to Covishield and Covaxin vaccines
In a major step forward in India’s fight against the Covid-19 pandemic, the Drugs Controller General of India…
AstraZeneca wins FDA approval for Tagrisso in adjuvant treatment of early-stage NSCLC patients with EGFR mutations
Find out how AstraZeneca’s expanded FDA approval for Tagrisso is transforming early-stage lung cancer treatment standards.
AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca…
BRILINTA FDA approval: A major step in reducing stroke risks in acute ischemic stroke and high-risk TIA patients
AstraZeneca has secured U.S. Food and Drug Administration (FDA) approval for BRILINTA (ticagrelor), expanding its use to reduce…
AstraZeneca resumes AZD1222 Covid-19 vaccine trials after safety review
AstraZeneca has announced the resumption of its clinical trials for the AZD1222 Covid-19 vaccine candidate in multiple countries,…
AstraZeneca’s AZD7442 to enter Phase 3 clinical trials for Covid-19 prevention and treatment
AstraZeneca has announced the progression of its monoclonal antibody combination, AZD7442, into two pivotal Phase 3 clinical trials.…
AstraZeneca’s Farxiga receives FDA breakthrough therapy designation for chronic kidney disease treatment
AstraZeneca’s Farxiga (dapagliflozin), a leading drug in the management of chronic kidney disease (CKD), has been granted Breakthrough…